Ken Griffin Syros Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.69 - $1.21 $72,939 - $127,907	-105,709 Reduced 82.52%	22,393 $22,000
Q1 2022 May 16, 2022	BUY	$1.02 - $3.8 $66,052 - $246,076	64,757 Added 102.23%	128,102 $152,000
Q4 2021 Feb 14, 2022	SELL	$3.26 - $4.66 $20,156 - $28,812	-6,183 Reduced 8.89%	63,345 $206,000
Q3 2021 Nov 15, 2021	SELL	$4.08 - $5.66 $47,817 - $66,335	-11,720 Reduced 14.42%	69,528 $311,000
Q2 2021 Aug 16, 2021	SELL	$5.01 - $7.48 $3.09 Million - $4.62 Million	-617,034 Reduced 88.36%	81,248 $442,000
Q1 2021 May 17, 2021	BUY	$7.19 - $14.95 $4.27 Million - $8.88 Million	594,005 Added 569.64%	698,282 $5.22 Million
Q4 2020 Feb 16, 2021	BUY	$6.66 - $14.66 $694,484 - $1.53 Million	104,277 New	104,277 $1.13 Million
Q3 2020 Nov 16, 2020	SELL	$8.69 - $14.47 $109,276 - $181,960	-12,575 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$5.21 - $11.03 $58,268 - $123,359	-11,184 Reduced 47.07%	12,575 $134,000
Q4 2018 Feb 14, 2019	BUY	$5.55 - $11.34 $30,813 - $62,959	5,552 Added 30.49%	23,759 $132,000
Q2 2018 Aug 10, 2018	BUY	$10.16 - $13.65 $184,983 - $248,525	18,207 New	18,207 $0
Q4 2017 Feb 09, 2018	SELL	$8.45 - $17.48 $559,804 - $1.16 Million	-66,249 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$13.52 - $23.75 $895,686 - $1.57 Million	66,249	66,249 $975,000

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.